Halving effort in acute stroke trials

被引:2
作者
Lees, KR
Milia, P
机构
[1] Univ Dept Med & Therapeut, Western Infirm, Glasgow G11 6NT, Lanark, Scotland
[2] Univ Perugia, Dept Neurosci, I-06100 Perugia, Italy
关键词
acute stroke; clinical trial; neuroprotection; outcome measure; sample size; variability;
D O I
10.1080/10641960600549355
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The expense and substantial effort required to conduct multicenter acute stroke trials are potentially limiting factors for progress in this field. To facilitate future work, we need to expand oil collaborative approaches to learn from existing trial delta sets, for example, using the Virtual International Stroke Trials Archive. Using these networks, vi,e call identify ways of reducing future effort in trials. The interaction between two or more selection criteria can be considered and can allow trials to concentrate oil the most informative patients. This has the potential to shorten the recruitment period and increase power simultaneously. Through enhanced training and certification of investigators in assessing outcomes, the main outcome measures may be assessed more accurately. This also should enhance study power. The choice of outcome scale and its method of analysis call have a profound effect on trial power and likely success. The Rankin scale may have advantages over the Barthel index. By combining these various approaches, acute stroke trials call be much more efficient.
引用
收藏
页码:309 / 312
页数:4
相关论文
共 11 条
[1]  
AbESTT Investigators, 2003, STROKE, V34, P253
[2]  
Adams H, 2003, CEREBROVASC DIS S4, V16, P52
[3]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[4]   NXY-059 for acute ischemic stroke [J].
Lees, KR ;
Zivin, JA ;
Ashwood, T ;
Davalos, A ;
Davis, SM ;
Diener, H ;
Grotta, J ;
Lyden, P ;
Shuaib, A ;
Hårdemark, H ;
Wasiewski, WW .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :588-600
[5]   Design of future acute-stroke treatment trials [J].
Lees, KR ;
Hankey, GJ ;
Hacke, W .
LANCET NEUROLOGY, 2003, 2 (01) :54-61
[6]   Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial [J].
Lees, KR ;
Asplund, K ;
Carolei, A ;
Davis, SM ;
Diener, HC ;
Kaste, M ;
Orgogozo, JM ;
Whitehead, J .
LANCET, 2000, 355 (9219) :1949-1954
[7]   Evaluation of designs for clinical trials of neuroprotective agents in head injury [J].
Machado, SG ;
Murray, GD ;
Teasdale, GM .
JOURNAL OF NEUROTRAUMA, 1999, 16 (12) :1131-1138
[8]   TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE ISCHEMIC STROKE [J].
MARLER, JR ;
BROTT, T ;
BRODERICK, J ;
KOTHARI, R ;
ODONOGHUE, M ;
BARSAN, W ;
TOMSICK, T ;
SPILKER, J ;
MILLER, R ;
SAUERBECK, L ;
JARRELL, J ;
KELLY, J ;
PERKINS, T ;
MCDONALD, T ;
RORICK, M ;
HICKEY, C ;
ARMITAGE, J ;
PERRY, C ;
THALINGER, K ;
RHUDE, R ;
SCHILL, J ;
BECKER, PS ;
HEATH, RS ;
ADAMS, D ;
REED, R ;
KLEI, M ;
HUGHES, S ;
ANTHONY, J ;
BAUDENDISTEL, D ;
ZADICOFF, C ;
RYMER, M ;
BETTINGER, I ;
LAUBINGER, P ;
SCHMERLER, M ;
MEIROSE, G ;
LYDEN, P ;
RAPP, K ;
BABCOCK, T ;
DAUM, P ;
PERSONA, D ;
BRODY, M ;
JACKSON, C ;
LEWIS, S ;
LISS, J ;
MAHDAVI, Z ;
ROTHROCK, J ;
TOM, T ;
ZWEIFLER, R ;
DUNFORD, J ;
ZIVIN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (24) :1581-1587
[9]   Use of the Barthel Index and Modified Rankin Scale in acute stroke trials [J].
Sulter, G ;
Steen, C ;
De Keyser, J .
STROKE, 1999, 30 (08) :1538-1541
[10]   Improving the assessment of outcomes in stroke - Use of a structured interview to assign grades on the modified Rankin Scale [J].
Wilson, JTL ;
Hareendran, A ;
Grant, M ;
Baird, T ;
Schulz, UGR ;
Muir, KW ;
Bone, I .
STROKE, 2002, 33 (09) :2243-2246